In terms of second-line efficacy, the MONALEESA-3 and PALOMA-3 studies both evaluated the combination of CDK4/6 inhibitors with fulvestrant in HR+/HER2− advanced breast cancer patients but differed in terms of patient populations and outcomes [9,10]. This evidence concerns the gene ERBB2 and breast carcinoma.